Proliferation and apoptosis of tumour cells before and after neoadjuvant therapy for high-grade extremity sarcomas: Divergent associations with tumour response and prognosis

Histopathology

Volumn 52, Issue 6, 2008, Pages 706-716

  Matsubara, T ^a   Eimoto, T ^a   Okabe, M ^a   Miyabe, S ^a   Fujiyoshi, Y ^a   Matsushita, Y ^a   Mizutani, J ^a   Yamada, S ^a   Otsuka, T ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Cell kinetics; Limb; Neoadjuvant therapy; Prognosis; Sarcoma

Indexed keywords

CASPASE 3; CISPLATIN; MINICHROMOSOME MAINTENANCE PROTEIN 2; PIRARUBICIN;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CELL KINETICS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EWING SARCOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTHERMIA; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIMB; LIMB TUMOR; LIPOSARCOMA; MALE; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, BONE TISSUE; PROGNOSIS; SARCOMA;

EID: 42649105790     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03015.x     Document Type: Article

References (42)

1. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006 106 1154 1161.
2. Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 2002 20 776 790.
3. Eilber FC, Rosen G, Eckardt J et al. Treatment-induced pathological necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol. 2001 19 3203 3209.
4. Hauben EI, Bielack S, Grimer R et al. Clinico-histologic parameters of osteosarcoma patients with late relapse. Eur. J. Cancer 2006 42 460 466.
5. Prosnitz LR, Maguire P, Anderson JM et al. The treatment of high-grade soft tissue sarcomas with preoperative thermo-radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1999 45 941 949.
6. Schoenfeld GS, Morris CG, Scarborough MT, Zlotecki RA. Adjuvant radiotherapy in the management of soft tissue sarcoma involving the distal extremities. Am. J. Clin. Oncol. 2006 29 62 65.
7. Otsuka T, Yonezawa M, Kamiyama F, Matsushita Y, Matsui N. Results of surgery and radio-hyperthermo-chemotherapy for patients with soft-tissue sarcoma. Int. J. Clin. Oncol. 2001 5 253 258.
8. Scotlandi K, Serra M, Manara MC et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer 1995 75 806 814.
9. Sondak VK, Chang AE. Clinical evaluation and treatment of soft tissue tumors. In Weiss SW, Goldblum JR eds. Enzinger and Weiss's soft tissue tumor, 4th edn. St Louis: Mosby, 2001 35.
10. Drobnjak M, Latres E, Pollack D et al. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki67 in adult soft-tissue sarcomas. J. Natl. Cancer Inst. 1994 86 549 554.
11. Choong PF, Akerman M, Willen H et al. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? APMIS 1995 103 797 805.
12. Yang P, Hirose T, Hasegawa T, Seki K, Sano T, Hizawa K. Prognostic implication of the p53 protein and Ki67 antigen immunohistochemistry in malignant fibrous histiocytoma. Cancer 1995 76 618 625.
13. Jensen V, Sorensen FB, Bentzen SM et al. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas. Histopathology 1998 32 536 546.
14. Kawauchi S, Fukuda T, Oda Y et al. Prognostic significance of apoptosis in synovial sarcoma: correlation with clinicopathological parameters, cell proliferative activity, and expression of apoptosis-related proteins. Mod. Pathol. 2000 13 755 765.
15. Hoos A, Stojadinovic A, Mastorides S et al. High Ki67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 2001 92 869 874.
16. Yoshida H, Watanabe M, Shomori K, Ito H, Miyazaki T. Apoptotic cell death and p53 expression in leiomyosarcoma of soft tissue origin. Yonago Acta Med. 2001 44 115 123.
17. Hasegawa T, Yamamoto S, Yokoyama R, Umeda T, Matsuno Y, Hirohashi S. Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer 2002 95 843 851.
18. Osaki M, Osaki M, Yamshita H, Shomori K, Yoshida H, Ito H. Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: correlations with Ki67 and p53 expression, and apoptosis. Int. J. Mol. Med. 2002 10 161 168.
19. Dan'ura T, Kawai A, Morimoto Y, Naito N, Yoshida A, Inoue H. Apoptosis and expression of its regulatory proteins in soft tissue sarcomas. Cancer Lett. 2002 178 167 174.
20. Sun B, Sun Y, Wang J, Zhao X, Wang X, Hao X. Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcoma. Eur. J. Cancer Prev. 2006 15 258 265.
21. Nakanishi H, Ohsawa M, Naka N, Uchida A, Ochi T, Aozasa K. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 1997 54 238 244.
22. Kearsey SE, Maiorano D, Holmes EC, Todorov IT. The role of MCM proteins in the cell cycle control of genome duplication. Bioassays 1996 18 183 190.
23. Stoeber K, Tlsty TD, Happerfield L et al. DNA replication licensing and human cell proliferation. J. Cell Sci. 2001 114 2027 2041.
24. Tomei LD. Apoptosis: a program for death or survival? In Tomei LD, Cope F eds. Apoptosis, the molecular basis of cell deat. New York: Cold Spring Harbor Laboratory Press, 1991 279 316.
25. Hirata H, Takahashi A, Kobayashi S et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med. 1998 187 587 600.
26. Frankfurt OS, Robb JA, Sugarbaker EV, Villa L. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases. Clin. Cancer Res. 1997 3 465 471.
27. Korkolopoulou P, Konstantinidou AE, Christodoulou P et al. Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA: relation to cell cycle regulators and survival. Urology 2000 56 516 520.
28. Donoghue S, Baden HS, Lauder I, Sobolewski S, Pringle JH. Immunohistochemical localization of caspase3 correlates with clinical outcome in B cell diffuse large-cell lymphoma. Cancer Res. 1999 59 5386 5391.
29. Fletcher CDM, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. In Kleihues P, Sobin LH eds. World Health Organization classification of tumour. Lyon: IARC Press, 2002, pp. 9 11.
30. Tateyama H, Tada T, Hattori H, Murase T, Li WX, Eimoto T. Effects of prefixation and fixation times on apoptosis detection by in situ end-labeling of fragmented DNA. Arch. Pathol. Lab. Med. 1998 122 252 255.
31. Archer CD, Parton M, Smith IE et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br. J. Cancer 2003 89 1035 1041.
32. Endl E, Gerdes J. The Ki67 protein: fascinating forms and an unknown function. Exp. Cell Res. 2000 257 231 237.
33. Todorov IT, Werness BA, Wang HQ et al. HsMCM2/BM28: a novel proliferation marker for human tumors and normal tissues. Lab. Invest. 1998 78 73 78.
34. Wester K, Wahlund E, Sundstrom C et al. Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen. Appl. Immunohistochem. Mol. Morphol. 2000 8 61 70.
35. Tsutsumi Y, Kamoshida S. Pitfalls and caveats in histochemically demonstrating apoptosis. Acta Histochem. Cytochem. 2003 36 271 280.
36. Cho Mar K, Eimoto T, Nagaya S, Tateyama H. Cell proliferation marker MCM2, but not Ki67, is helpful for distinguishing between minimally invasive follicular carcinoma and follicular adenoma of the thyroid. Histopathology 2006 48 801 807.
37. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J. Histochem. Cytochem. 2002 50 449 454.
38. Boyer MJ, Tannock IF. Cellular and molecular basis of chemotherapy. In Tannock IF, Hill RP eds. The basic science of oncology. New York: McGraw-Hill, 1998 353 355.
39. Yonezawa M, Otsuka T, Matsui N et al. Hyperthermia induces apoptosis in malignant fibrous histiocytoma cells in vitro. Int. J. Cancer 1996 66 347 351.
40. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch. 2005 446 489 496.
41. Soini Y, Paakko P, Lehto V-P. Histopathological evaluation of apoptosis in cancer. Am. J. Pathol. 1998 153 1041 1053.
42. Belloc F, Belaud-Rotureau MA, Lavignolle V et al. Flow cytometry detection of caspase 3 activation in preapoptotic leukemic cells. Cytometry 2000 40 151 160.